Potential Effects of Novel Sensorimotor Upper Limb Rehabilitation Paradigm
NCT ID: NCT06870682
Last Updated: 2025-05-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
NA
10 participants
INTERVENTIONAL
2025-02-18
2025-10-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Robot-based Therapy for Upper Limb Sensorimotor Impairments After Stroke
NCT05007002
Towards Understanding Upper Limb Rehabilitation After Stroke
NCT04721561
Robotic Assessment of Upper Limb Passive and Active Sensory Processing in Healthy Adults
NCT04723212
Validity and Reliability of Sensorimotor Processing Paradigm
NCT06382558
Efficacy Study of an Interactive Robot for the Rehabilitation of the Upper Limb in Acute Stroke Patients
NCT02079779
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Optionally, if the participants is willing and able to, additional MRI and/or fNIRS assessments will be added to give a first idea regarding changes in brain structure, function and activity because of this novel therapy approach. This study will inform the investigators to finalize the protocol for a following RCT.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ROBUST intervention
The participants will be measured a first time with both robot-based and clinical assessments. Thereafter, the participant follows a 4-week control period, only receiving standard care. After the control period, a second measuring moment is planned using the same outcome measures as during the first measurement. Then, a the 4-week intervention is planned, whereby participants get 48 hours additional sensorimotor upper limb training. They will come 3 times per week to Leuven for a therapy session of two hours. During these therapy sessions, they receive one hour robot-based therapy and one hour transfer package training with a therapist. Additionally, they follow 6 times a week a 1-hour home program. After this intervention period, they are measured a last time using the same outcome measures as during the previous measuring moments.
ROBUST
During a 4-week intervention, participants get 48 hours additional sensorimotor upper limb training. They will come 3 times per week to Leuven for a therapy session of two hours. During these therapy sessions, they receive one hour robot-based therapy and one hour transfer package training with a therapist. Additionally, they follow 6 times a week a 1-hour home program. This intervention can be distinguished from others since it integrates both motor and sensory function, with focus on sensory processing. It combines robot-based therapy, a transfer package to daily activities, and a home program.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ROBUST
During a 4-week intervention, participants get 48 hours additional sensorimotor upper limb training. They will come 3 times per week to Leuven for a therapy session of two hours. During these therapy sessions, they receive one hour robot-based therapy and one hour transfer package training with a therapist. Additionally, they follow 6 times a week a 1-hour home program. This intervention can be distinguished from others since it integrates both motor and sensory function, with focus on sensory processing. It combines robot-based therapy, a transfer package to daily activities, and a home program.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. A first-ever unilateral, supra-tentorial stroke, as defined by WHO (rapidly developing clinical signs of focal (or global) disturbance of cerebral function, with symptoms lasting 24 hours or longer or leading to death, with no apparent cause other than vascular origin)
3. ≥18 years old
4. Being in the chronic phase after stroke, i.e. \> 6 months post stroke
5. Motor impairment in the upper limb, defined as Fugl-Meyer score \>22 out of 66 to demonstrate moderate to full upper limb motor function (patients scoring \<23 out of 66 will not be able to comply with the KINARM protocol)
6. Residual sensory upper limb impairment, defined as Tactile Discrimination Test score \<24 out of 25
7. Impaired functionality, defined as Action Research Arm Test score \<52 out of 57
8. Manageable spasticity for KINARM tasks
Exclusion Criteria
2. Having severe communication or cognitive deficits that interfere with the protocol
3. Any disorder, which in the investigator's opinion might jeopardise participant's safety or compliance with the CIP
4. Contraindications for robot-based therapy (e.g., uncontrolled epilepsy)
5. Participation in another clinical investigation
6. Having uncontrolled head movements (e.g. tremor), only relevant if participant is willing to receive the additional fNIRS assessments
7. Having any contra-indications for MRI, only relevant if participant is willing to receive the additional MRI assessments:
* Pacemaker
* Implantable Cardioverter Defibrillator (ICD)
* Cochlear implant
* Internal Insulin-pump
* Deep brain stimulation
* Any other metal device in body
* Claustrophobia
* Having a history of a neuropsychiatric or neurologic disorder before the diagnosis of stroke (e.g., depression, traumatic brain injury)
* Use of psychoactive medication before the diagnosis of stroke (e.g., anti-depressive medication)
* Use (or history of use) of drugs/alcohol
* Being pregnant
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
KU Leuven
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Prof Geert Verheyden
Prof. Dr.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
KU Leuven
Leuven, , Belgium
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
C2M/23/060
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
S69003
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.